Journey Medical Corporation DERM Accounts Receivable, Credit Loss Expense (Reversal)

Accounts Receivable, Credit Loss Expense (Reversal) at other companies

HRO

HarrowHROW

——

Other financials

Income statement

See full

Revenue$16.0M+21.5%

Gross profit$9.7M+16.7%

Operating income-$1.5M+55.1%

Net income-$2.2M+45.2%

EPS (diluted)-$0.08+55.6%

Balance sheet

See full

Cash & equivalents$27.2M+29.2%

Total debt$25.5M+1.2%

Total equity$30.8M+43.1%

Total assets$91.5M+7.7%

Cash flow

See full

Operating cash flow$2.9M+203%

CapEx$3.8M—

Free cash flow-$6.0M—

Valuation

See full

Market cap$194.94M+20.9%

Enterprise value$193.19M+16.2%

P/S3×+0.2×

Profitability

See full

Gross margin65.4%-1.0pp

Operating margin-9.8%—

Net margin-14.8%—

FCF margin-43%—

Returns & leverage

See full

Return on equity-36.6%—

Debt / equity0.8×-0.3×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:ProvisionForDoubtfulAccounts.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's accounts receivable, credit loss expense (reversal).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Journey Medical Corporation's accounts receivable, credit loss expense (reversal)?: Journey Medical Corporation (DERM) reported accounts receivable, credit loss expense (reversal) of $30K in Q1 2026.
How has Journey Medical Corporation's accounts receivable, credit loss expense (reversal) changed year-over-year?: Journey Medical Corporation's accounts receivable, credit loss expense (reversal) decreased by 84.6% year-over-year, from $195K to $30K.